And in ligand-receptor interaction, the B cells activation group showed more active CSF, CXCL, and MHC-I signaling pathway, while CD22 was inhibited, indicating that the B cells activation group improved anti-tumor immunity through cell-cell interactions (Supplementary Fig. 4g). This evidence concerns the gene CD22 and neoplasm.